Prognostic Value of IgM in Covid-19 Infection

NCT05092594 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-04-12

No results posted yet for this study

Summary

The primary objective of the research is to study the relation between the presence and /or the anti SARS-Co-V-2 IgM level in an early stage of COVID-19 infection, and the evolution of the illness.

Conditions

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Jean-Louis Gaillard, MD, PhD · Microbiological Laboratory - CHU Ambroise Paré - APHP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2022-05-31
Completion
2022-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05092594 on ClinicalTrials.gov